Hedge Fund Modeling Basic - Multiples

When I'm using a multiple to determine a 12-36M price target, I was wondering what the convention was regarding the use of Calendar Year vs. Fiscal Year for companies where the 2 don't align.

Typically when spreading public comps, I use CY to standardize for different FY ends. 

If I'm applying a '26E P/E multiple to my 2026E EPS to arrive at a target stock price, that P/E multiple will be a benchmark multiple based on my CY comp spreads so intuitively, it makes sense to me to use the CY2026E EPS vs. FY. 

In some standard HF modeling examples I have access to, I see that it's all based on FY for the 12-36 month price targets so was curious how professionals do it. 

I understand that a DCF is based on FY given that aligns with company reporting. 

4 Comments
 

When determining a 12-36 month price target using multiples, the convention can vary depending on the context and the specific modeling approach. Here's a breakdown based on the most helpful WSO content:

  1. Calendar Year (CY) vs. Fiscal Year (FY):

    • Using CY is common when spreading public comps to standardize across companies with different fiscal year ends. This ensures consistency and comparability in your analysis.
    • If you're applying a '26E P/E multiple derived from CY comp spreads, it makes intuitive sense to use CY2026E EPS to align with the benchmark multiple. This approach maintains consistency between the multiple and the earnings figure.
  2. Hedge Fund Modeling Examples:

    • In some hedge fund modeling examples, professionals use FY for 12-36 month price targets. This is often because FY aligns directly with company-reported financials, making it easier to tie back to actual company guidance and historical data.
  3. Professional Practice:

    • There isn't a strict "one-size-fits-all" rule. The choice between CY and FY often depends on the specific context of the analysis, the preferences of the analyst or fund, and the availability of data.
    • For DCF models, as you noted, FY is typically used since it aligns with company reporting and facilitates a more accurate projection of cash flows.
  4. Key Takeaway:

    • If your P/E multiple is based on CY comps, stick with CY EPS for consistency.
    • If you're working within a framework or example that uses FY, ensure your multiples and earnings align with FY to avoid mismatches.

Ultimately, the most important factor is maintaining consistency between the multiple and the earnings figure you're applying it to.

Sources: Biotech finance part 2: valuation methodologies and modeling considerations, Biotech finance part 2: valuation methodologies and modeling considerations, January 2016 Data Update 8: Pricing, with an end of month update, DCFs no longer necessary?, Accretion Follow-Up - Technical Question

I'm an AI bot trained on the most helpful WSO content across 17+ years.
 
[Comment removed by mod team]
 
Most Helpful

Sapiente molestiae saepe eos quae ut. Tempora officia fugiat molestias. Magnam et quis voluptatem ea unde natus reiciendis. Asperiores culpa atque aliquid placeat voluptate ab. Quidem dolore quia velit asperiores quia aut aliquam. Qui eius fugit qui ducimus possimus.

Et quibusdam aspernatur sit cum error. Nesciunt voluptatem veniam magnam sapiente.

Eum aut expedita unde repellendus accusantium sapiente voluptate. Atque dolor ullam quasi quia. Soluta dolores aut corporis neque voluptatum saepe similique. Exercitationem voluptates hic officia.

Dolorem ad fugit dolores dolorem necessitatibus eum dolorum. Cum molestias quos ea et modi itaque earum. Officia facilis culpa vel deleniti vel cumque. Quam dicta quibusdam rem rem quis. Voluptatibus at doloribus voluptatibus quia eum explicabo magnam.

 

Nihil quis autem dolor aut qui. Quidem voluptatum quibusdam velit. Ab explicabo numquam velit ratione omnis. Commodi voluptatem distinctio praesentium id esse adipisci dolore esse. Nam nulla aut vel unde.

Reiciendis autem at aliquid ut. Architecto est iure corrupti. Ab inventore ipsam veritatis quidem enim. Labore nihil animi perspiciatis. Cupiditate voluptate ut saepe porro fugit consectetur aspernatur commodi. Quisquam neque commodi placeat impedit corporis enim.

Et eaque laboriosam rem odio eos. Doloribus eos aut pariatur. Quia id nemo et dolore omnis qui perferendis. Ad neque enim accusamus aspernatur illum consectetur magnam.

Career Advancement Opportunities

November 2026 Hedge Fund

  • Point72 99.0%
  • D.E. Shaw 98.0%
  • AQR Capital Management 97.1%
  • Citadel Investment Group 96.1%
  • Magnetar Capital 95.1%

Overall Employee Satisfaction

November 2026 Hedge Fund

  • Magnetar Capital 99.0%
  • D.E. Shaw 98.0%
  • Blackstone Group 97.0%
  • Citadel Investment Group 96.0%
  • Two Sigma Investments 95.0%

Professional Growth Opportunities

November 2026 Hedge Fund

  • AQR Capital Management 99.0%
  • Point72 98.1%
  • D.E. Shaw 97.1%
  • Citadel Investment Group 96.1%
  • Magnetar Capital 95.1%

Total Avg Compensation

November 2026 Hedge Fund

  • Portfolio Manager (9) $1,648
  • Vice President (27) $464
  • Director/MD (12) $355
  • NA (9) $320
  • Engineer/Quant (83) $287
  • 3rd+ Year Associate (26) $284
  • Manager (4) $282
  • 2nd Year Associate (32) $253
  • 1st Year Associate (77) $193
  • Analysts (235) $177
  • Intern/Summer Associate (29) $145
  • Junior Trader (5) $102
  • Intern/Summer Analyst (277) $95
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
kanon's picture
kanon
99.0
3
BankonBanking's picture
BankonBanking
99.0
4
Secyh62's picture
Secyh62
99.0
5
GameTheory's picture
GameTheory
98.9
6
Betsy Massar's picture
Betsy Massar
98.9
7
CompBanker's picture
CompBanker
98.9
8
dosk17's picture
dosk17
98.9
9
DrApeman's picture
DrApeman
98.9
10
Mimbs's picture
Mimbs
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”